Sygnature Discovery Limited

Based in the UK, Sygnature Discovery Limited is a pharmaceutical service provider specializing in integrated drug discovery solutions to assist clients in the drug development process. Sygnature Discovery Limited, founded in 2004, operates from its headquarters in Nottingham, UK, focusing on drug discovery services. The company was acquired by Five Arrows Principal Investments from Phoenix Equity Partners in June 2021. The company has executed a total of 2 deals, with the most recent deal occurring on June 18, 2021.

Sygnature Discovery specializes in integrated drug discovery services, offering in vivo pharmacology, medicinal chemistry, bioscience, and drug metabolism and pharmacokinetics (DMPK) consultancy. Their services address challenges in areas including oncology, fibrotic diseases, metabolic diseases, inflammation, immunology, anti-infectives, neuroscience, and respiratory conditions. They serve clients in North America and Europe, including pharmaceutical and biotechnology firms, through collaborative partnerships to enhance the drug discovery timeline. In 2024, Sygnature Discovery generated revenue of USD 87.

91 mn with an EBITDA of USD 16. 28 mn. The company primarily earns revenue through project-based contracts with pharmaceutical and biotechnology clients, engaging in phases of drug discovery such as hit identification and formulation development. Sygnature Discovery is focused on expanding its service offerings and enhancing client collaborations in the drug discovery sector.

The company aims to penetrate new geographic markets and target regions such as North America and Europe by 2025. The recent acquisition by Five Arrows Principal Investments is expected to facilitate growth initiatives and support the expansion of their drug discovery capabilities.